Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Trinity Biotech (TRIB) Finished Goods (2016 - 2025)

Trinity Biotech's Finished Goods history spans 7 years, with the latest figure at $3.6 million for Q4 2025.

On a quarterly basis, Finished Goods fell 17.18% to $3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 17.18% decrease, with the full-year FY2025 number at $3.6 million, down 17.18% from a year prior.
Finished Goods hit $3.6 million in Q4 2025 for Trinity Biotech, down from $4.4 million in the prior quarter.
Over the last five years, Finished Goods for TRIB hit a ceiling of $4.4 million in Q4 2024 and a floor of $3.6 million in Q4 2025.